About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

Clemson University baseball head coach Erik Bakich shares the mentality behind his team's decision to shake hands with ...

Biocity Biopharmaceutics Co. Ltd.’s selective endothelin receptor type A antagonist, SC-0062, met the primary endpoint of reducing proteinuria in a phase II diabetic kidney disease cohort. Conducted ...

The following is a summary of “Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy,” published in the ...

BioCity Biopharma’s selective endothelin receptor type A (ETA) antagonist has reduced excess proteins in the urine of ...

Cigarette smoke comprises over 7,000 chemicals, including nicotine, tar, carbon monoxide, and heavy metals such as cadmium.

Q4 2024 Earnings Call Transcript February 21, 2025 Operator: Good afternoon, and welcome to the Travere Therapeutics Fourth ...

Preeclampsia, a complication of pregnancy characterized by high blood pressure and high levels of protein in the urine ...

Wendy Kuohung, MD, associate professor of obstetrics & gynecology at Boston University Chobanian & Avedisian School of Medicine, has been awarded a two-year, Discovery Research Grant from March of ...

Travere Therapeutics Inc (TVTX) reports significant growth in Phil Spari sales and strategic progress, despite facing ...

Symptom scores remained stable over time, with similar QOL trends in both treatment arms.

A drop in blood pressure is a common complication during hemodialysis. In medical jargon, the phenomenon is called intradialytic hypotension. It happens when the body is unable to compensate properly ...